Mercury Bio Welcomes Casey Perkins as VP to Propel Corporate Strategy and Business Development

Mercury Bio Welcomes Casey Perkins as Vice President of Corporate Strategy and Business Development

Mercury Bio, a pioneering company in the realm of intracellular delivery for central nervous system (CNS) therapeutics, has announced the significant appointment of Cassandra "Casey" Perkins as its new Vice President of Corporate Strategy and Business Development. This strategic move is aimed at bolstering the company’s mission to deliver groundbreaking applications through its proprietary yEV™ platform.

With an extensive career spanning over 25 years in biotech and pharmaceuticals, Perkins brings a wealth of experience that encompasses commercial strategy, market access, channel operations, and patient services, particularly in the domains of rare and orphan diseases, as well as in cell and gene therapies targeting conditions in neurology, oncology, and immunology. Her previous accolades include playing a crucial role in the commercialization of transformational therapies like ZOLGENSMA®. Her proven ability to develop patient-centric approaches, coupled with strategic growth frameworks, makes her an invaluable asset to the Mercury Bio team.

In her new role, Perkins is set to lead corporate strategy and business development efforts focused on establishing strategic partnerships and enhancing investor relations. This comes at a pivotal time for Mercury Bio as it accelerates the development of its innovative intracellular drug delivery platform utilizing yeast-derived exosomes. The yEV™ platform represents a novel mechanism that facilitates the transmission of therapeutic proteins, RNA, and other molecular agents between cells, unlocking exciting new pathways for treatment.

Perkins’ appointment aligns perfectly with Mercury Bio’s goals, especially following the company’s recent success in pre-clinical research that demonstrated the effective delivery of proteins into neurons, crossing the blood-brain barrier in murine models. This breakthrough has profound implications for the treatment of debilitating neurological disorders such as Alzheimer’s and Parkinson’s diseases. In light of these developments, Perkins will collaborate closely with Mercury Bio's Chief Scientific Officer, Richard Sayre, Ph.D., and the company’s CEO, Bruce McCormick, to further divulge the unique capabilities of the yEV™ platform during the upcoming Biotech Showcase scheduled in San Francisco, California.

Bruce McCormick expressed his enthusiasm about Perkins joining the team, stating, "Casey’s experience and patient-first leadership are exactly what Mercury Bio needs as we advance our platform and pipeline. Her strategic perspective will be vital as we explore the potential yEV™ offers to pharmaceutical companies seeking a viable way to transmit their neurologics into the brain."

In addition to her professional endeavors, Perkins is dedicated to volunteer work at the Mayo Clinic Phoenix Cancer Infusion Center and serves on the Policy and Advocacy Committee for Tina's Warriors, a nonprofit organization that supports individuals facing rare cancers.

About Mercury Bio

Mercury Bio was established with the vision of harnessing scientific advancements in genomic research to create a next-generation biomolecular drug delivery platform. Their technology prioritizes patient safety and drug efficacy while aiming to reduce adverse side effects through cell-specific targeting and an innovative drug encapsulation system within biological vesicles. This results in an advanced, scalable, and cost-effective drug delivery system that aims to maximize the therapeutic potential of protein therapeutics, RNA therapeutics, and small-molecule drugs.

As the healthcare landscape evolves, the integration of experienced leaders like Casey Perkins into pioneering organizations like Mercury Bio exemplifies the commitment to enhancing patient outcomes and driving forward therapeutic innovations. With her at the helm of corporate strategy, the future looks bright for Mercury Bio and its revolutionary drug delivery solutions.